Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for revumenib in Related Substance Name (approximate match)

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Revumenib

LZ0M43NNF2

Search for Structure

Status:

US Approved Rx (2024)

Source:

NDA218944

(2024)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944

First approved in 2024

Source:

NDA218944

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944

Class (Stereo):

CHEMICAL (ACHIRAL)

MENIN

W8U7X588F2

Subunit 1 (615) Similarity Search

Sequence Search

Subunit 1 (615) Similarity Search

Status:

Other

Class:

PROTEIN

Revumenib Citrate

YL4RYN734D

Search for Structure

Status:

US Approved Rx (2024)

Source:

NDA218944

(2024)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944

First approved in 2024

Source:

NDA218944

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944

Class (Stereo):

CHEMICAL (ACHIRAL)

Revumenib sesquifumarate

75HI05N8HS

Search for Structure

Status:

US Approved Rx (2024)

Source:

NDA218944

(2024)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944

First approved in 2024

Source:

NDA218944

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944

Class (Stereo):

CHEMICAL (ACHIRAL)

Structure of Revumenib

ACHIRAL

Protein

Structure of Revumenib Citrate

ACHIRAL

Revumenib Citrate

Structure of Revumenib sesquifumarate

ACHIRAL

Revumenib sesquifumarate

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1